Patents Assigned to Novozymes Biopharma UK Limited
  • Publication number: 20140128326
    Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 8, 2014
    Applicants: Novozymes Biopharma DK A/S, University of OSLO, Novozymes Biopharma UK Limited, Novozymes A/S
    Inventors: Jason Cameron, Karen Ann Delahay, Jens Erik Nielsen, Andrew Plumridge, Jan Terje Andersen
  • Publication number: 20120322739
    Abstract: The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: May 4, 2012
    Publication date: December 20, 2012
    Applicants: Novozymes Biopharma UK Limited, Novozymes Biopharma DK A/S, Novozymes A/S, University of Oslo
    Inventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Delahay
  • Publication number: 20100222267
    Abstract: The present invention provides a recombinant protein comprising the sequence of a transferrin mutant, wherein Ser415 is mutated to an amino acid which does not allow glycosylation at Asn413 and/or wherein Thr613 is mutated to an amino acid which does not allow glycosylation as Asn611. It also provides polynucleotides encoding the same and methods of making and using said recombinant protein.
    Type: Application
    Filed: June 13, 2008
    Publication date: September 2, 2010
    Applicant: Novozymes Biopharma UK Limited.
    Inventors: Christopher John Arthur Finnis, Darrell Sleep, Joanna Hay
  • Patent number: 7601515
    Abstract: A process is provided for the preparation of albumin from a yeast culture medium which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, and which is essentially non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises separating the yeast from the culture medium to yield an albumin solution; subjecting the albumin solution to positive mode cation exchange, affinity, and positive mode anion exchange chromatography; and concentrating and formulating the albumin with sodium octanoate and sodium chloride.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: October 13, 2009
    Assignee: Novozymes Biopharma UK Limited
    Inventors: Andrew Robert Goodey, Darell Sleep, Hendrik Van Urk, Stephen Berezenko, John Rodney Woodrow, Richard Alan Johnson, Patricia Carol Wood, Stephen James Burton, Alan Victor Quirk
  • Publication number: 20090227775
    Abstract: The invention relates to proteins comprising HIV fusion inhibiting peptides, such as T-20 and/or T-1249 peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity.
    Type: Application
    Filed: March 10, 2009
    Publication date: September 10, 2009
    Applicant: NOVOZYMES BIOPHARMA UK LIMITED
    Inventors: Hans-Peter HAUSER, Thomas Weimer, Darrell Sleep
  • Publication number: 20090197316
    Abstract: Protein particles are prepared by causing or allowing protein molecules dispersed in a liquid medium at a concentration of 8 mg.mL-1 or greater to react in the presence of a zero-length crosslinker, so as to produce protein particles comprising protein molecules that are covalently bonded together. The protein particles may be produced with sizes in the sub-micron range with closely defined sizes and size distributions. The particles have applications in many fields, but are useful inter alia for the delivery of therapeutic agents and other agents, eg imaging contrast agents, to the body.
    Type: Application
    Filed: July 13, 2007
    Publication date: August 6, 2009
    Applicants: Novozymes Biopharma UK Limited, Upperton Limited
    Inventors: Richard Alan Johnson, John Rodney Woodrow
  • Publication number: 20090175893
    Abstract: The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits.
    Type: Application
    Filed: January 23, 2009
    Publication date: July 9, 2009
    Applicant: NOVOZYMES BIOPHARMA UK LIMITED
    Inventors: Peter Mertins, Ilhan Celik, Oliver Kisker, Darrell Sleep, Joanna Hay, Hans-Peter Hauser
  • Publication number: 20090171070
    Abstract: A process is provided for the preparation of a highly pure recombinant albumin solution having a nickel ion content of less than 100 ng per gram of albumin. The process comprises subjecting a recombinant albumin to a series of chromatography, concentration, and diafiltration steps.
    Type: Application
    Filed: September 9, 2008
    Publication date: July 2, 2009
    Applicant: NOVOZYMES BIOPHARMA UK LIMITED
    Inventors: Hendrik Van Urk, David John Mead, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michel Gaston Joseph Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Darrell Sleep, Jean-Luc Bernard Veron
  • Patent number: 7550432
    Abstract: The invention describes albumin fusion proteins comprising growth hormone and serum albumin. The invention also describes nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acid molecules, host cells transformed with these vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally, the invention describes compositions comprising the albumin fusion proteins, and methods of treating patients in need of growth hormone, comprising administering the albumin fusion proteins of the invention.
    Type: Grant
    Filed: December 23, 2005
    Date of Patent: June 23, 2009
    Assignee: Novozymes Biopharma UK Limited
    Inventor: David James Ballance
  • Publication number: 20080293638
    Abstract: The invention relates to a fusion protein comprising an albumin, or a fragment or a variant or a derivative thereof and at least one biologically active peptide which activates the ciliary neurotrophic factor (CNTF) receptor, or a fragment or variant or a derivative thereof.
    Type: Application
    Filed: July 3, 2008
    Publication date: November 27, 2008
    Applicant: NOVOZYMES BIOPHARMA UK LIMITED
    Inventors: Mathias Jurs, Thomas Weimer, Hans-Peter Hauser, Darrell Sleep
  • Patent number: 7435410
    Abstract: Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: October 14, 2008
    Assignee: Novozymes Biopharma UK Limited
    Inventors: Reinhard Fleer, Alain Fournier, Jean-Dominique Guitton, Gérard Jung, Patrice Yeh
  • Patent number: 7410779
    Abstract: The invention includes biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant of human serum albumin, methods for the preparation of such fusion polypeptides, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing such fusion polypeptides.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: August 12, 2008
    Assignee: Novozymes Biopharma UK Limited
    Inventors: Reinhard Fleer, Alain Fournier, Jean-Dominique Guitton, Gérard Jung, Patrice Yeh